AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 61 min read$ARQT

Burnett Patrick sold $25K of ARQT

Burnett Patrick (See Remarks) sold 955 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.12 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 6, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new guidance, trial results, regulatory actions, or deal terms.

02

Market read

A small, scheduled insider sale is unlikely to drive fundamentals, but it can marginally influence sentiment around ARQT.

03

What to watch

Traders may overreact to insider sales; the key is whether there is a pattern of repeated sales outside scheduled plans, which is not evidenced here.

Relevance 2/10Novelty 2/10Timing: filed Aug 5, transaction dated Aug 3 (insider sale disclosure)

Background

The article is an SEC Form 4 insider transaction report for Arcutis Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics insider Burnett Patrick sold 955 shares in an open-market transaction on Aug 3 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling appears.

Evidence & confidence

The filing is a Form 4 open-market sale with a pre-arranged 10b5-1 plan; no new company-specific operational or financial information is provided.

Market effects

Sector

Minimal; insider sale does not signal sector-wide change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Arcutis Biotherapeutics, Inc.

    US-listed biotherapeutics company subject of the Form 4 insider sale disclosure.

  • insider
    Burnett Patrick

    Officer who sold 955 shares on Aug 3 at $26.1168/share under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

OCT 20
$ARQTHigh

Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb

Arcutis Biotherapeutics (ARQT) shares rose 10.65% to $31.89 after upgrades from Guggenheim and Cantor Fitzgerald, with price targets raised to $44 and $48 respectively. The company reported Q2 net income of $15M, up from a loss last year, driven by its eczema and psoriasis treatment Zoryve. ARQT raised its 2026 sales guidance to $525M-$540M. Institutional investors increased their holdings in Q2.

insidermonkey.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and steroid use at dermatology conferences. Phase 2 data showed 34.4% of infants with atopic dermatitis achieved clear or almost clear skin after 4 weeks. Phase 3 data showed 66.4% of patients with scalp psoriasis achieved clear or almost clear skin at Week 8. The company also presented research on seborrheic dermatitis and corticosteroid hesitancy. ARQT stock was up 1.32% on Thursday and is up 1.84% in premarket trading.

rttnews.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis presents data on ZORYVE cream for infant eczema

Arcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.

investing.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.

globenewswire.com2 min